Introduction
============

There are currently no agreed recommendations on how to investigate children for cardiopulmonary involvement in Juvenile Systemic Sclerosis (JSSc). The aim of screening is to detect disease early to facilitate early aggressive therapy and improve outcomes. Cardiopulmonary involvement is the leading cause of death in JSSc and cardiopulmonary at diagnosis incurs a worse outcome \[1\]. Most deaths occur early in the disease course \[1, 2\].

Objectives
==========

To develop recommendations for investigation of cardiopulmonary in JSSc, based on paediatric evidence and where this was lacking, consensus expert agreement.

Methods
=======

Members of the PRES Scleroderma Working Group were invited to participate; additionally a paediatric cardiologist was invited. A nominal group technique was used. 75% consensus was defined as agreement.

Results
=======

Table [1](#T1){ref-type="table"} shows the recommendations for screening for cardiopulmonary at baseline and at defined time points from diagnosis. Other recommendations agreed by the group which are relevant at any stage in the disease course are as follows (in Table [1](#T1){ref-type="table"}).

###### 

Recommendations for screening for cardiopulmonary involvement in JSSc at baseline and follow-up (75% consensus defined as agreement)

  --------------------- -------------------------------------------------------------- --------------------
  **Cardiopulmonary**   **Baseline**                                                   

                                                                                       

                        All patients should undergo:\                                  
                        - BP\                                                          
                        - 12 lead ECG\                                                 
                        - 24 hour ECG\                                                 
                        - ECHO with Doppler\                                           
                        - Cardiac MRI with gadolinium\                                 
                        - HRCT thorax\                                                 
                        - PFT with DLCO\                                               
                        - 6MWT                                                         

                                                                                       

                        **Follow-up screening (for first 5 years from diagnosis)\***   

                                                                                       

                        6 monthly                                                      12 lead ECG\
                                                                                       ECHO with doppler\
                                                                                       6MWT\
                                                                                       PFT with DLCO

                                                                                       

                        Annual                                                         24hr ECG

                                                                                       

                        At 3 years                                                     Repeat HRCT
  --------------------- -------------------------------------------------------------- --------------------

\*screening guidelines are based on asymptomatic patients. However, children may need more frequent monitoring depending on clinical status and abnormalities detected on previous investigation.

Recommendations are based on low grade evidence and in the most part from expert consensus opinion with extrapolation from adult studies.

Conclusion
==========

JSSc has a significant mortality particularly early on in the disease course. The objective of an aggressive screening program is to identify cardiopulmonary involvement at a stage which may be amenable to treatment. The recommendations developed by this group aim to standardise care and improve outcomes in this rare disease.
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BP: blood pressure; ECG: electrocardiogram; ECHO: echocardiogram; MRI: magnetic resonance imaging; HRCT: high resolution computerised tomography; PFT DLCO: pulmonary function tests with diffusion capacity of lung for carbon monoxide; 6MWT: 6 minute walk test; NT BNP: *N-terminal pro*-*brain natriuretic peptide; GORD: gastro-oesophageal reflux disease*.
